Production (Stage)
Cadrenal Therapeutics, Inc.
CVKD
$13.70
-$0.16-1.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.25M | 2.74M | 1.67M | 1.21M | 1.13M |
| Depreciation & Amortization | 5.50K | 400.00 | 400.00 | 500.00 | 600.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.93M | 4.28M | 2.46M | 2.47M | 1.76M |
| Operating Income | -3.93M | -4.28M | -2.46M | -2.47M | -1.76M |
| Income Before Tax | -3.85M | -4.19M | -2.41M | -2.39M | -1.66M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.85M | -4.19M | -2.41M | -2.39M | -1.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.85M | -4.19M | -2.41M | -2.39M | -1.66M |
| EBIT | -3.93M | -4.28M | -2.46M | -2.47M | -1.76M |
| EBITDA | -3.92M | -4.28M | -2.46M | -2.47M | -1.76M |
| EPS Basic | -2.09 | -2.55 | -2.18 | -2.24 | -1.56 |
| Normalized Basic EPS | -1.30 | -1.60 | -1.36 | -1.40 | -0.97 |
| EPS Diluted | -2.09 | -2.55 | -2.18 | -2.24 | -1.56 |
| Normalized Diluted EPS | -1.30 | -1.60 | -1.36 | -1.40 | -0.97 |
| Average Basic Shares Outstanding | 1.84M | 1.64M | 1.10M | 1.07M | 1.07M |
| Average Diluted Shares Outstanding | 1.84M | 1.64M | 1.10M | 1.07M | 1.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |